Table 1.
Characteristic | Total no. of patients, n (%) | Angiosarcoma, n (%) | Other sarcoma, n (%) | P a |
---|---|---|---|---|
96 | 50 | 46 | ||
Surgery type | ||||
Mastectomy | 44 (46) | 11 (22) | 33 (72) | <0.05 |
Resection | 52 (54) | 39 (78) | 13 (28) | |
Primary BC tumor size | ||||
<20 mm | 53 (55) | 34 (68) | 19 (41) | 0.127 |
≥20 mm | 26 (27) | 12 (24) | 14 (30) | |
Missing | 17 (18) | 4 (8) | 13 (28) | |
Histology | ||||
Ductal | 61 (64) | 35 (70) | 26 (57) | <0.05 |
Lobular | 14 (15) | 10 (20) | 4 (9) | |
Other | 15 (16) | 4 (8) | 11 (24) | |
Missing | 6 (6) | 1 (2) | 5 (11) | |
Grade | ||||
1 | 19 (20) | 16 (32) | 3 (7) | <0.05 |
2 | 41 (43) | 26 (52) | 15 (33) | |
3 | 9 (9) | 2 (4) | 7 (15) | |
Missing | 27 (28) | 6 (12) | 21 (46) | |
Node status | ||||
Negative | 53 (55) | 34 (68) | 19 (41) | <0.05 |
Positive | 42 (44) | 16 (32) | 26 (57) | |
Missing | 1 (1) | 0 | 1 (2) | |
Estrogen receptor status | ||||
Negative | 8 (8) | 3 (6) | 5 (11) | 0.439 |
Positive | 57 (59) | 38 (76) | 19 (41) | |
Missing | 31 (32) | 9 (18) | 22 (48) | |
Progesterone receptor status | ||||
Negative | 17 (18) | 12 (24) | 5 (11) | 0.316 |
Positive | 46 (48) | 29 (58) | 17 (37) | |
Missing | 33 (34) | 9 (18) | 24 (52) | |
HER2 overexpression | ||||
Negative | 31 (32) | 20 (40) | 11 (24) | 1.00 |
Positive | 2 (2) | 1 (2) | 1 (2) | |
Missing | 63 (66) | 29 (58) | 34 (74) | |
Adjuvant endocrine therapy | ||||
No | 63 (66) | 32 (64) | 31 (67) | 0.840 |
Yes | 33 (34) | 18 (36) | 15 (33) | |
Adjuvant chemotherapy | ||||
No | 76 (79) | 48 (96) | 28 (61) | <0.05 |
Yes | 20 (21) | 2 (4) | 18 (39) | |
Axillary lymph node RT | ||||
No | 49 (51) | 37 (74) | 12 (26) | <0.05 |
Yes | 46 (48) | 13 (26) | 33 (72) | |
Missing | 1 (1) | 0 | 1 (2) | |
Radiation boost at tumor bed | ||||
No | 79 (82) | 37 (74) | 42 (91) | <0.05 |
Yes | 17 (18) | 13 (26) | 4 (9) |
HER2, human epidermal receptor 2; RT, radiation therapy.
Either chi‐squared or Fisher's exact test.